Lu AE04621
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Lu AE04621 is a dopamine receptor agonist which is or was under development for the treatment of Parkinson's disease but has not been marketed.[1][2][3] It is taken orally.[1] The drug is said to be a prodrug of the catecholamine Lu AA40326 and to act as a dual dopamine D1 and D2 receptor agonist.[1][2][3][4] Lu AE04621 is or was under development by Lundbeck.[1][2] As of November 2023, it is in phase 1 clinical trials and has been since at least 2016, but no recent development has been reported since February 2019.[1] The chemical structure of Lu AE04621 has not yet been disclosed.[1][2][3] However, it may be a prodrug of 5,6-diOH-DPAT or a related approach.[2]
Other namesLu-AE04621; Lu AE 04621; LuAE04621
ATC code
- None
| Clinical data | |
|---|---|
| Other names | Lu-AE04621; Lu AE 04621; LuAE04621 |
| Routes of administration | Oral[1] |
| Drug class | Dopamine receptor agonist; Dopamine D1 and D2 receptor agonist |
| ATC code |
|
